Advertisement
EpiPen price backlash comes as consumers pay greater share

EpiPen price backlash comes as consumers pay greater share

By Adam Rubenfire  |  August 25, 2016

The controversy surrounding Mylan's EpiPen pricing suggests drugmakers have been slow to adapt to an environment in which millions of Americans must pay thousands of dollars out of pocket before their coverage kicks in.

Mylan boosts EpiPen patient programs, doesn't budge on price

By Associated Press  |  August 25, 2016

Mylan is bulking up programs that help patients pay for its EpiPen emergency allergy treatment after weathering heated criticism about an average cost that has soared over the past decade. But the drugmaker didn't budge on its price hikes Thursday.

Senator seeks FTC investigation into EpiPen prices

Senator seeks FTC investigation into EpiPen prices

By Adam Rubenfire  |  August 22, 2016

Sen. Amy Klobuchar, a ranking member of the Antitrust Subcommittee, wants the Federal Trade Commission to investigate the “enormous increase in the price of EpiPens,” following a number of recent media reports regarding the devices' high cost.

Valeant, attempting to normalize operations, names new CFO

By Associated Press  |  August 22, 2016

Valeant Pharmaceuticals replaced Robert Rosiello as chief financial officer as the embattled company attempts to normalize operations amid a host of ongoing investigations and class action lawsuits.

Pfizer spends $14B on Medivation in cancer fight

Pfizer spends $14B on Medivation in cancer fight

By Associated Press  |  August 22, 2016

Pfizer will pay about $14 billion to buy cancer drug developer Medivation in a cash deal aimed at fortifying its hold in one of the hottest and most lucrative areas of medicine.

Volunteers sought as race to develop a Zika vaccine heats up

By Associated Press  |  August 18, 2016

Wanted: Volunteers willing to be infected with the Zika virus for science. It may sound bizarre, but researchers are planning just such a study—this winter, when mosquitoes aren't biting—to help speed development of much-needed Zika vaccines.

Medicare Part D spending rose 17% in 2014 because of high-cost drugs

Medicare Part D spending rose 17% in 2014 because of high-cost drugs

By Shannon Muchmore  |  August 18, 2016

The drug with by far the highest cost, despite the lowest claim count of the 10 most expensive, was Gilead's hepatitis C treatment Sovaldi at more than $3.1 billion. Next were Nexium, which treats gastroesophageal reflux disease, and the cholesterol drug Crestor.

Study finds FluMist effective, contrary to CDC findings

By Steven Ross Johnson  |  August 16, 2016

New evidence contradicts a federal panel's recommendations that found the nasal form of the influenza vaccine to be ineffective in fighting the virus. But the differing conclusions may have resulted from the way in which the data were collected.

Advertisement
Modern Healthcare Daily

Award winning coverage of healthcare business and policy news.

The Modern Healthcare app includes a personalized home screen, strong search functionality and immediate downloads from the industry's leading healthcare media brand.